xiaodan fu

Dr. xiaodan fu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
QWQihui Wu
Qihui Wu
RTRuotong Tian
Ruotong Tian
JLJiaxin Liu
Jiaxin Liu
Chunlin OuChunlin Ou
Chunlin Ou
YLYinmin Li
Yinmin Li
XFxiaodan fu
xiaodan fu
Background: Dysregulation of chromatin regulators (CRs) can perturb the tumor immune microenvironment, but the underlying mechanism remains unclear. We focused on uterine corpus endometrial carcinoma (UCEC) and used gene expression data from TCGA-UCEC to investigate this mechanism.Methods: We used weighted gene co-expression network analysis (WGCNA) and consensus clustering algorithm to classify UCEC patients into Cluster_L and Cluster_H. TME-associated CRs were identified using WGCNA and differential gene expression analysis. A CR risk score (CRRS) was constructed using univariate Cox and LASSO-Cox regression analyses. A nomogram was developed based on CRRS and clinicopathologic factors to predict patients' prognosis.Results: Lower CRRS was associated with lower grade, more benign molecular subtypes, and improved survival. Patients with low CRRS showed abundant immune infiltration, a higher mutation burden, fewer CNVs, and better response to immunotherapy. Moreover, low CRRS patients were more sensitive to 24 chemotherapeutic agents.Conclusion: A comprehensive assessment of CRRS could identify immune activation and improve the efficacy of UCEC treatments.

5 April 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
QWQihui Wu
Qihui Wu
RTRuotong Tian
Ruotong Tian
XHXiaoyun He
Xiaoyun He
JLJiaxin Liu
Jiaxin Liu
Chunlin OuChunlin Ou
Chunlin Ou
XFxiaodan fu
xiaodan fu
Background: High-grade serous ovarian cancer (HGSOC) is a highly lethal gynecological cancer that requires accurate prognostic models and personalized treatment strategies. The tumor microenvironment (TME) is crucial for disease progression and treatment. Machine learning-based integration is a powerful tool for identifying predictive biomarkers and developing prognostic models. Hence, an immune-related risk model developed using machine learning-based integration could improve prognostic prediction and guide personalized treatment for HGSOC.Methods: During the bioinformatic study in HGSOC, we performed (i) consensus clustering to identify immune subtypes based on signatures of immune and stromal cells, (ii) differentially expressed genes and univariate Cox regression analysis to derive TME- and prognosis-related genes, (iii) machine learning-based procedures constructed by ten independent machine learning algorithms to screen and construct a TME-related risk score (TMErisk), and (iv) evaluation of the effect of TMErisk on the deconstruction of TME, indication of genomic instability, and guidance of immunotherapy and chemotherapy.Results: We identified two different immune microenvironment phenotypes and a robust and clinically practicable prognostic scoring system. TMErisk demonstrated superior performance over most clinical features and other published signatures in predicting HGSOC prognosis across cohorts. The low TMErisk group with a notably favorable prognosis was characterized by BRCA1 mutation, activation of immunity, and a better immune response. Conversely, the high TMErisk group was significantly associated with C-X-C motif chemokine ligands deletion and carcinogenic activation pathways. Additionally, low TMErisk group patients were more responsive to eleven candidate agents.Conclusion: Our study developed a novel immune-related risk model that predicts the prognosis of ovarian cancer patients using machine learning-based integration. Additionally, the study not only depicts the diversity of cell components in the TME of HGSOC but also guides the development of potential therapeutic techniques for addressing tumor immunosuppression and enhancing the response to cancer therapy.

25 July 2025 in Theranostics
Verified
Journal Article
Open access
PDF file
YZYuxiu Zhang
Yuxiu Zhang
YXYuanyuan Xu
Yuanyuan Xu
QWQihui Wu
Qihui Wu
XFxiaodan fu
xiaodan fu
YLYinmin Li
Yinmin Li
ALAnqi Li
Anqi Li
Leukocyte immunoglobulin-like receptors, subfamily B (LILRBs), are a class of critical immunosuppressive receptors that contribute to immune homeostasis by transmitting suppressive signals upon binding to ligands such as major histocompatibility complex class I molecules. They play key roles in modulating both innate and adaptive immune responses. This review summarizes the structural features, ligand interactions, signaling pathways, and expression regulation of LILRBs, and discusses their roles in immune cell function and disease progression, particularly in the tumor microenvironment. We also review current progress in the development of LILRB-targeted therapies for hematological malignancies and solid tumors and outline the challenges and future directions in translating these findings into clinical applications. By integrating recent advances, this review provides a framework for understanding the potential of LILRBs as therapeutic targets in cancer and immune-related disorders.

24 August 2024 in Translational Oncology
Verified
Journal Article
Open access
YWYan Wang
Yan Wang
QWQihui Wu
Qihui Wu
JLJiaxin Liu
Jiaxin Liu
XWXuan Wang
Xuan Wang
JXJialing Xie
Jialing Xie
YLYimin Li
Yimin Li
Despite its involvement in regulating various cellular functions, the expression and role of WD repeat-containing protein 77 (WDR77) in cancer remain elusive. This study aims to explore the expression and potential roles of WDR77 across multiple cancers, with a particular focus on its relevance in colorectal cancer (CRC). We obtained WDR77 RNA-seq data, mutations, CNVs, and DNA methylation data from the TCGA, GTEx, and GEO databases to investigate its expression patterns and prognostic value. Additionally, we examined the correlation between WDR77 expression and somatic mutations, copy number variations, DNA methylation, and mRNA modifications. We utilized GSVA, GSEA algorithms, and CRISPR KO data from the Dependency Map database to explore WDR77's potential biological functions. The association between WDR77 and the tumor immune microenvironment was investigated using ESTIMATE and IOBR algorithms. Finally, we assessed WDR77 expression in CRC and its impact on cell proliferation through qRT-PCR, Western blotting, immunohistochemistry, CCK8, colony formation, and EdU assays. WDR77 was upregulated in various tumors and correlated with poor patient prognosis. Its high expression positively correlated with pathways related to cell proliferation and negatively correlated with immune-related pathways. In CRC, WDR77 expression was associated with specific clinical features, genomic alterations, and immune microenvironment characteristics. Experimental validation confirmed upregulated WDR77 expression in CRC tissues and cells, with WDR77 knockdown significantly inhibiting CRC cell proliferation. WDR77 holds potential as an oncogene and biological marker in various cancers, particularly CRC.

14 July 2025 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
ALAnqi Li
Anqi Li
QWQihui Wu
Qihui Wu
YXYuanyuan Xu
Yuanyuan Xu
YGYijin Gu
Yijin Gu
XWXuan Wang
Xuan Wang
YLYinmin Li
Yinmin Li
Serine metabolism plays a pivotal role in cancer progression by supporting essential biosynthetic pathways and energy production. Exploring the intricacies of serine metabolism in cancer may uncover novel therapeutic opportunities. This study presents a comprehensive pan‐cancer analysis of serine metabolism‐related genes (SMGs), with a particular emphasis on colorectal cancer (CRC), to elucidate their expression patterns, genetic alterations and clinical significance. We performed a pan‐cancer analysis of SMGs using integrating transcriptomic, genomic and epigenetic data from TCGA and GTEx databases. For CRC, we performed in‐depth analyses comparing expression patterns between tumour and normal tissues, examining prognostic significance and exploring associations with the tumour microenvironment (TME). The distribution patterns of SMGs within the TME were further investigated using single‐cell RNA sequencing and immunohistochemistry. Key SMGs, including PHGDH, SLC1A5 and SLC38A2, were validated in two independent real‐world cohorts of CRC. Pan‐cancer analysis revealed that SMGs are differentially expressed across tumour types, with their dysregulation associated with copy number alterations and epigenetic modifications. In CRC, aberrant SMG expression is significantly associated with clinical outcomes, key signalling pathways and the TME. Notably, PHGDH was consistently upregulated in CRC and associated with poor prognosis, while SLC1A5 emerged as a potential biomarker for liver metastasis. This study underscores the importance of SMGs, particularly PHGDH, SLC1A5 and SLC38A2, in CRC progression and prognosis. Our findings offer valuable insights into SMGs as a potential therapeutic target and provide a foundation for developing personalised metabolic interventions in CRC.

1 October 2021 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
MSM Couselo Seijas
M Couselo Seijas
AVA Molares Vila
A Molares Vila
SLS B Bravo Lopez
S B Bravo Lopez
AFAngel L. Fernández-González
Angel L. Fernández-González
CBC Almenglo Buzon
C Almenglo Buzon
SPS Eiras Penas
S Eiras Penas
Background: The association between epicardial adipose tissue (EAT) and atrial fibrillation (AF) was already described by several authors. In fact, botulinum toxin injection in this tissue reduces new-onset AF after open-heart surgery. Our previous results showed an elevation of adiposity in epicardial stromal vascular cells (SVC), assessed by the higher levels of fatty acid-binding protein 4 (FABP4) in AF patients; and a higher lipid accumulation in these cells after chronic acetylcholine treatment. We wanted to identify the proteins released from EAT SVC in presence/absence of mature adipocytes, that could be exerting a paracrine effect over the myocardium. The identification of these proteins might shed light on possible triggers in epicardial SVC and the mechanisms underlying botulinum toxin benefits on AF. Material and methods: Proteomic studies were performed in 32 samples from 8 patients undergoing open-heart surgery (4 with and 4 without AF). Epicardial SVC were isolated by collagenase digestion and cultured in M199 medium. Then, cells were induced or not to adipocyte differentiation. After this intervention, cells were treated or not with acetylcholine (10uM) for 30 min. Conditioned medium was stored until be used. Differential released proteins were identified by nano-high performance liquid chromatography (HPLC) and Triple-Time of flying (TOF) analysis, and quantified by SWATH-Ms proteomics anaylisis. Results: The quantitative proteomic approach has identified 111 common proteins in EAT SVC from patients with and without AF. A 79,3% of the genes which encoded the proteins identified were citoplasmic. A 78,4% were classified as components of the cellular exosomes, followed by genes related with centrosome (37,1%), nucleosome (15,5%), lysosomes (40,5%) and nucleolus (37,1%). Acute cholinergic treatment with ACh at 10 uM decreased α-defensin 3 (DEFA3, ID: 59666; p-value = 0,0297) secretion from EAT SVC of AF patients in comparison with EAT SVC from non-AF patients. In the same line, Peptidyl-prolyl cis-trans isomerase A (PPIA, ID: P62937) showed a lower secretion from SVC of AF patients (p=0,0326). After adipogenesis-induction, adipocyte presence modified the protein secretion under ACh treatment: Differences between AF and non-AF patients lied on 2 different proteins: profilin 1 (PFN1, ID: P07737, p-value = 0,0286) and β-enolase (ENO3, ID: P13929, p-value = 0,0414), showing a higher and lower secretion in AF patients regarding non-AF patients, respectively. Conclusions: EAT SVC showed a differential protein secretion according adipocyte and AF presence. Although further studies are needed, the proteins differentially secreted in EAT SVC are related to inflammation (DEFA3), structure (PFN1) and glucose metabolism (ENO3), pointing the pathways that could be modified in AF patients. Funding Acknowledgement: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Plan Estatal de I+D+I 2016-2020 and ISCIII-Subdirecciόn General de Evaluaciόn y Fomento de la Investigaciόn el Fondo Europeo de Desarrollo Regional (FEDER) Figure 1. Common proteins secreted from EAT SVCFigure 2. Differentially secreted proteins in AF